AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 587 Thousand EUR | -36.68% |
| 2022 | 927 Thousand EUR | -38.03% |
| 2021 | 1.49 Million EUR | -1.19% |
| 2020 | 1.51 Million EUR | 8.92% |
| 2019 | 1.39 Million EUR | -4.34% |
| 2018 | 1.45 Million EUR | -10.2% |
| 2017 | 1.61 Million EUR | 53.36% |
| 2016 | 1.05 Million EUR | -45.76% |
| 2015 | 1.94 Million EUR | 14.08% |
| 2014 | 1.7 Million EUR | 6.43% |
| 2013 | 1.6 Million EUR | 45.37% |
| 2012 | 1.1 Million EUR | 37.24% |
| 2011 | 803 Thousand EUR | 48.7% |
| 2010 | 540 Thousand EUR | 225.3% |
| 2009 | 166 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 268 Thousand EUR | 0.0% |
| 2023 Q3 | 179 Thousand EUR | 116.51% |
| 2023 Q4 | 179 Thousand EUR | 0.0% |
| 2023 FY | 587 Thousand EUR | -36.68% |
| 2023 Q1 | 114.5 Thousand EUR | -56.87% |
| 2023 Q2 | -1.08 Million EUR | -1046.72% |
| 2022 Q3 | 101 Thousand EUR | 242.25% |
| 2022 Q2 | -71 Thousand EUR | -130.15% |
| 2022 Q1 | 235.5 Thousand EUR | 132.66% |
| 2022 FY | 927 Thousand EUR | -38.03% |
| 2022 Q4 | 265.5 Thousand EUR | 162.87% |
| 2021 Q2 | 486 Thousand EUR | 19.26% |
| 2021 Q1 | 407.5 Thousand EUR | -47.32% |
| 2021 FY | 1.49 Million EUR | -1.19% |
| 2021 Q4 | -721 Thousand EUR | -313.63% |
| 2021 Q3 | 337.5 Thousand EUR | -30.56% |
| 2020 Q2 | 209 Thousand EUR | -42.97% |
| 2020 Q3 | 385.5 Thousand EUR | 84.45% |
| 2020 FY | 1.51 Million EUR | 8.92% |
| 2020 Q1 | 366.5 Thousand EUR | 71.26% |
| 2020 Q4 | 773.5 Thousand EUR | 100.65% |
| 2019 Q2 | 102 Thousand EUR | -69.55% |
| 2019 FY | 1.39 Million EUR | -4.34% |
| 2019 Q1 | 335 Thousand EUR | 7.03% |
| 2019 Q4 | 214 Thousand EUR | -40.56% |
| 2019 Q3 | 360 Thousand EUR | 252.94% |
| 2018 Q2 | 413.5 Thousand EUR | 0.0% |
| 2018 Q1 | 413.5 Thousand EUR | 5.22% |
| 2018 FY | 1.45 Million EUR | -10.2% |
| 2018 Q4 | 313 Thousand EUR | 0.0% |
| 2018 Q3 | 313 Thousand EUR | -24.3% |
| 2017 FY | 1.61 Million EUR | 53.36% |
| 2017 Q4 | 393 Thousand EUR | 0.0% |
| 2017 Q1 | 416 Thousand EUR | 102.43% |
| 2017 Q2 | 416 Thousand EUR | 0.0% |
| 2017 Q3 | 393 Thousand EUR | -5.53% |
| 2016 Q4 | 205.5 Thousand EUR | 0.0% |
| 2016 Q3 | 205.5 Thousand EUR | -36.18% |
| 2016 Q1 | 322 Thousand EUR | -21.37% |
| 2016 FY | 1.05 Million EUR | -45.76% |
| 2016 Q2 | 322 Thousand EUR | 0.0% |
| 2015 FY | 1.94 Million EUR | 14.08% |
| 2015 Q2 | 563 Thousand EUR | 0.0% |
| 2015 Q4 | 409.5 Thousand EUR | 0.0% |
| 2015 Q3 | 409.5 Thousand EUR | -27.26% |
| 2015 Q1 | 563 Thousand EUR | 37.82% |
| 2014 Q4 | 408.5 Thousand EUR | 0.0% |
| 2014 FY | 1.7 Million EUR | 6.43% |
| 2014 Q1 | 443.99 Thousand EUR | 22.48% |
| 2014 Q2 | 443.99 Thousand EUR | 0.0% |
| 2014 Q3 | 408.5 Thousand EUR | -8.0% |
| 2013 Q2 | 438.5 Thousand EUR | 0.0% |
| 2013 Q3 | 362.5 Thousand EUR | -17.33% |
| 2013 Q4 | 362.5 Thousand EUR | 0.0% |
| 2013 FY | 1.6 Million EUR | 45.37% |
| 2013 Q1 | 438.5 Thousand EUR | 0.0% |
| 2012 FY | 1.1 Million EUR | 37.24% |
| 2011 FY | 803 Thousand EUR | 48.7% |
| 2010 FY | 540 Thousand EUR | 225.3% |
| 2009 FY | 166 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | 99.836% |
| Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 99.879% |
| Vetoquinol SA | 291.37 Million EUR | 99.799% |
| Valneva SE | 52.83 Million EUR | 98.889% |
| Nanobiotix S.A. | 42.35 Million EUR | 98.614% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 55.732% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 118.966% |
| BioSenic S.A. | 543 Thousand EUR | -8.103% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 85.003% |
| Formycon AG | 23.3 Million EUR | 97.481% |